Dolastatin 10 Derivatives Enhancing ADC Cytotoxic Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of ADCs is limited by the scarcity of high-potency cytotoxic agents, as current cytotoxic drugs do not meet the required potency levels, hindering the advancement of this therapeutic approach.
Innovation Solution
The development of novel dolastatin 10 derivatives with specific structural modifications to enhance their cytotoxic potency, which are then integrated into antibody-drug conjugates (ADCs) to target specific cell surface proteins and release active drugs within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cytotoxic drugs are used in ADCs, then the ADC development can proceed, but the cytotoxic potency is insufficient to meet the required 10-1000 folds higher potency levels
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dolastatin 10 derivatives at specific positions (N-terminal and C-terminal) to enhance cytotoxic potency. The patent describes synthesizing derivatives with modified amino acid sequences and chemical groups to achieve the required 10-1000 folds higher potency while maintaining ADC applicability
Solution Approach 2:
The patent segments the dolastatin 10 molecule into specific functional regions (N-terminal region, C-terminal region, and central core) and independently modifies each segment. The patent shows specific modifications at the N-terminal (positions 1-3) and C-terminal (positions 7-10) while maintaining the central microtubule-targeting core, allowing optimized potency without compromising mechanism of action
2Reliability
If more cytotoxic drug candidates are developed to meet potency requirements, then the therapeutic potential of ADCs is enhanced, but the development complexity and time increase
Solution Approach 1:
The patent applies preliminary action by establishing a systematic approach to modify dolastatin 10 derivatives before ADC conjugation. The patent describes pre-synthesizing optimized derivatives with enhanced potency and stability, preparing them in advance for conjugation to antibodies, thereby reducing overall development time
Solution Approach 2:
The patent creates universal dolastatin 10 derivative platforms that can be conjugated to multiple different antibody types and target antigens. The patent describes designing modular derivatives with flexible conjugation sites that work across different ADC platforms (e.g., anti-HER2, anti-CD20, anti-CD30), reducing the need to develop separate cytotoxic agents for each indication
3Reliability
If structural modifications are made to dolastatin 10 to enhance potency, then cytotoxic activity increases, but the synthesis complexity increases
Solution Approach 1:
The patent applies local quality by making targeted modifications only at specific positions of the dolastatin 10 molecule where they most effectively enhance potency. The patent shows modifications concentrated at the N-terminal (affecting cell penetration and stability) and C-terminal (affecting cytotoxicity), while leaving the central microtubule-binding core unchanged, thereby simplifying synthesis compared to complete structural redesign
Solution Approach 2:
The patent employs dynamic synthesis approaches where the dolastatin 10 core is first synthesized, then functional groups are selectively introduced or modified at specific positions. The patent describes using protected amino acid intermediates and stepwise coupling reactions that allow flexible modification of specific regions without affecting the entire molecule, reducing overall synthesis complexity
Data Source
AI summary
Derivatives of dolastatin 10 and uses thereof, the structures of which are shown as formula I, II, III and IV are provided.